Low-dose and long-term olaparib treatment sensitizes mda-mb-231 and sum1315 triple-negative breast cancers spheroids to fractioned radiotherapy

HIGHLIGHTS

• who: Clémence Dubois and colleagues from the Université Clermont Auvergne, INSERM, Imagerie Moléculaire et Stratégies Théranostiques, have published the research work: Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy, in the Journal: (JOURNAL)
• what: This analysis showed a strong decrease in survival for cells treated with 1 to 5 µM Olaparib for 120 h and 10 Gy compared to 120 h Olaparib treatment alone. This analysis showed that the beneficial of the co-treatment (Olaparib + RX) compared to . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.